Data / Drug companies / Omnivium Pharmaceuticals LLC.
Omnivium Pharmaceuticals LLC.: 14 products in the FDA NDC directory, labeler code 81665
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Omnivium Pharmaceuticals LLC. (labeler code 81665) lists 14 products in the FDA National Drug Code Directory, covering 9 finished drugs by generic name. By type: 14 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 19, 2025.
The request: Watch Omnivium Pharmaceuticals LLC. (FDA labeler code 81665): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 81665
- Products in commercial distribution
- 14
- Packages
- 21
- Finished drugs by generic name
- 9
- Prescription products
- 14
- Over the counter products
- 0
- Controlled substance products
- Schedule II 2, Schedule IV 1
- Flagged as original packager
- 14 of 14 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- June 11, 2020
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 10 | 71.4% |
| Authorized generics (NDA) | 3 | 21.4% |
| New drug applications (NDA) | 1 | 7.1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 14 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Levetiracetam | 2 | 87 |
| Cocaine hydrochloride nasal | 2 | 1 |
| Isosorbide mononitrate | 2 | 25 |
| Sodium phenylacetate and sodium benzoate | 2 | 7 |
| Isoniazid | 2 | 15 |
| Sodium bicarbonate | 1 | 51 |
| Cromolyn sodium | 1 | 11 |
| Diethylpropion hydrochloride | 1 | 12 |
| Carboprost tromethamine | 1 | 22 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 4 | 28.6% |
| Tablet, extended release | 3 | 21.4% |
| Solution | 2 | 14.3% |
| Injection, solution, concentrate | 2 | 14.3% |
| Injection, solution | 2 | 14.3% |
| Solution, concentrate | 1 | 7.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Nitrate Vasodilator | 2 |
| Nitrogen Binding Agent | 2 |
| Antimycobacterial | 2 |
| Mast Cell Stabilizer | 1 |
| Sympathomimetic Amine Anorectic | 1 |
| Prostaglandin Analog | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Diethylpropion Hydrochloride ER | 81665-109 | Tablet, extended release | Generic drugs (ANDA) | September 19, 2025 |
| SODIUM PHENYLACETATE and SODIUM BENZOATE | 81665-204 | Injection, solution, concentrate | Generic drugs (ANDA) | May 15, 2025 |
| Carboprost tromethamine | 81665-202 | Injection, solution | Generic drugs (ANDA) | May 15, 2025 |
| SODIUM PHENYLACETATE and SODIUM BENZOATE | 81665-203 | Injection, solution, concentrate | Generic drugs (ANDA) | February 25, 2025 |
| Isoniazid | 81665-108 | Tablet | Generic drugs (ANDA) | October 15, 2024 |
| Isoniazid | 81665-107 | Tablet | Generic drugs (ANDA) | October 15, 2024 |
| Cromolyn sodium | 81665-104 | Solution, concentrate | Generic drugs (ANDA) | August 31, 2024 |
| Numbrino | 81665-300 | Solution | New drug applications (NDA) | June 19, 2024 |
| Isosorbide mononitrate | 81665-103 | Tablet | Authorized generics (NDA) | May 2, 2024 |
| Isosorbide mononitrate | 81665-102 | Tablet | Authorized generics (NDA) | May 2, 2024 |
| Cocaine hydrochloride nasal | 81665-301 | Solution | Authorized generics (NDA) | October 15, 2023 |
| Sodium Bicarbonate | 81665-200 | Injection, solution | Generic drugs (ANDA) | June 16, 2023 |
| LEVETIRACETAM Extended-release | 81665-101 | Tablet, extended release | Generic drugs (ANDA) | May 5, 2023 |
| LEVETIRACETAM Extended-release | 81665-100 | Tablet, extended release | Generic drugs (ANDA) | June 11, 2020 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.